Key Highlights

  • The UK CMA accepted in principle a proposed remedy on October 8, 2026.
  • Brink's agreed to propose divesting NoteMachine and TestLink UK.
  • Second-quarter revenue grew 7% and adjusted EBITDA rose 11%.
  • The board declared a $0.255 quarterly dividend, ex-dividend November 2.

The Brink's Company (NYSE:BCO) received a regulatory step forward on October 8, 2026, when the UK Competition and Markets Authority accepted in principle a proposed remedy for its planned NCR Atleos acquisition. The company still expects the deal to close in early the first quarter of 2027, and it appears in the S&P MidCap 400 constituent list.

Latest Company Context

Brink's said on September 30 it agreed to propose divesting NoteMachine and TestLink UK to address CMA concerns, and shareholders of both companies approved the acquisition on June 30, 2026. On October 1 the board declared a quarterly dividend of $0.255 per share, with an ex-dividend date of November 2. For the second quarter (reported August 5), revenue grew 7%, adjusted EBITDA rose 11%, net income rose 2% and GAAP EPS was $1.07, up 4%, and guidance was raised. Trailing-twelve-month revenue is $5.48 billion and market capitalisation about $4.26 billion.

Key Business and Index Drivers

The company cited a 14th consecutive quarter of mid-teens or greater organic growth in its ATM managed services and digital retail solutions. The NCR Atleos deal would deepen its ATM services exposure. Regulatory remedies can alter the expected synergies. S&P MidCap 400 membership may support liquidity. Four analysts rate the shares favourably with an average target of $146.33.

What Investors Should Watch

Investors may watch for final CMA decisions, other approvals and the closing date. The next earnings report is estimated for November 4, 2026, and could update guidance and deal financing. The ex-dividend date and leverage after closing are other areas to follow.

A Remedy Accepted in Principle Keeps the NCR Atleos Timetable Alive

Brink's is balancing organic growth with a major acquisition now moving through review. The proposed NoteMachine and TestLink UK divestitures address CMA concerns, and the closing date now depends on final regulatory decisions.